Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.42 |
| ▸ | GCG | P01275 | 11/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | GIPR | P48546 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718203 | 0.89 | GCGR (0.45) | GCGRGCGTP53SMN1; SMN2MEN1 | |
| SCHEMBL720571 | 0.88 | GCGR (0.53) | GCGRGCGGLP1RGIPRSMN1; SMN2 | |
| SCHEMBL720038 | 0.87 | GCGR (0.53) | GCGRGCGGLP1RGIPRSMN1; SMN2 | |
| SCHEMBL719279 | 0.85 | GCGR (0.49) | GCGRGCGGLP1RGIPRSMN1; SMN2 | |
| SCHEMBL2669909 | 0.83 | GCGR (0.41) | GCGRGCGGLP1RGIPRTP53 | |
| SCHEMBL717966 | 0.81 | GCGR (0.48) | GCGRGCGGLP1RGIPR | |
| SCHEMBL721163 | 0.80 | GCG (0.38) | GCGRGCGGLP1RGIPRTP53 | |
| SCHEMBL720764 | 0.80 | RCE1 (0.46) | GCGRTP53PDE7A | |
| SCHEMBL716869 | 0.79 | MEN1 (0.41) | GCGRGCGGLP1RGIPRPDE7A | |
| SCHEMBL720861 | 0.79 | PDE7A (0.40) | GCGRGCGTP53PDE7AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCGR 90/4885GCG 35/4885GLP1R 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.